Home > Insider Trading > Filing (0001104659-16-159835)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1660719	Aralez Pharmaceuticals Inc.	ARLZ	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1537250	Paul Robert Harris	C/O Aralez Pharmaceuticals Inc., 7100 West Credit Avenue, Suite 101 Mississauga A6 L5N 0E4		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares, Without Par Value	Acquisiton	2016-11-28	20,000	$3.92	614,094	No	4	M	Direct
Common Shares, Without Par Value	Disposition	2016-11-28	20,000	$4.65	594,094	No	4	S	Direct
Common Shares, Without Par Value	Acquisiton	2016-11-29	104,778	$3.92	698,872	No	4	M	Direct
Common Shares, Without Par Value	Disposition	2016-11-29	104,778	$4.99	594,094	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares, Without Par Value	Employee Stock Option (right to buy)	Disposition	2016-11-28	20,000	$0.00	20,000	$3.92
Common Shares, Without Par Value	Employee Stock Option (right to buy)	Disposition	2016-11-29	104,778	$0.00	104,778	$3.92

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
104,778		2016-12-01	No	4	M	Direct
0		2016-12-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares, Without Par Value	600,188	Indirect	By spouse

Footnotes

Price is presented in Canadian dollars.
The exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2016, as amended.
Price is presented in United States dollars.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2016, as amended.
This transaction was executed in multiple trades at prices ranging from $4.76 to $5.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The option was exercisable as of the Reporting Person's previous filing on Form 3, dated as of February 8, 2016.